People's Journal of Scientific Research
Published June 1, 2015 | Version v1
Journal article Open

Clinical Features, Diagnosis and Management of Hirsutism

Authors/Creators

  • 1. Department of Dermatology, People's College of Medical Sciences & Research Center, Bhopal
  • 2. Consultant Gynecologist, Marie Stopes international, Bhopal

Description

Hirsutism is a common clinical condition encountered in day to day practice. It means excessive growth of terminal hair in women with male characteristics and locations and is usually related to hormonal factors, mainly to increased level of androgens. In female the main sources of androgens, which can produce hirsutism are the adrenal gland (Dehydroepiandrosterone sulfate: DHEA-S) and the ovaries (U 4-androstenedione). Pituitary gland (prolactin) and liver (Sex hormone binding globulin) can also cause hirsutism in few cases. Ectopic hormone production by some tumors may also be responsible for hirsutism, but in few patients all biochemical parameters are absolutely normal. Therefore, it may be sometimes very difficult to understand the pathology of hirsutism in a given case. And one may find difficult to establish the cause of hirsutism and so the treatment, because depending on the origin of the hirsutism, the treatment is based on antiandrogens, oral contraceptive pills, glucocorticoids, GnRH antagonists in association of topical or dermato-cosmetic therapy or lasers. We conducted a literature search and analyzed the causes, types, investigations and management aspects of hirsutism that may help one to understand and manage a case of hirsutism.

Files

13 Dr Vivek Kumar Dey.pdf

Files (189.5 kB)

Name Size Download all
md5:cee4e98ef42d422810c3fa24fb58b14c
189.5 kB Preview Download

Additional details

References

  • 1. Bulent O, Yildiz, Sheila Bolour, Keslie Woods et al. Visually scoring hirsutism. Hum Reprod Update, 2010; 16 (1): 51-4.
  • 2. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Meta, 2004; 89(2):453-2.
  • 3. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Relative Prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab, 2006; 91(1):2–6.
  • 4. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemio, 2004; 57(12):1279-7.
  • 5. Danforth CH. Studies on hair with special reference to hypertrichosis. Arch Dermatol Syphilo, 1925;12(1):76- 4.
  • 6. Simpson NB, Barth JH. Hair Patterns: Hirsutes and androgenetic alopecia. In: Dawber RP, editor. Diseases of the Hair and Scalp. Oxford: Blackwell Science; 1997.
  • 7. Rosenfield RL. Hirsutism and the variable response of the pilosebaceous unit to androgen. J Investig Dermatol Symp Proc, 2005;10(3):205-8.
  • 8. Garn SM. Types and distribution of the hair in man. Ann N Y Acad Sci 1951;53 (3):498-7.
  • 9. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev, 2000; 21(4):347-2.
  • 10. Wendelin DS, Pope DN, Mallory SB. Hypertrichosis. J Am Acad Dermatol, 2003;48(2):161-9
  • 11. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab, 1961; 21:1440-7.
  • 12. Beek CH. A study on extension and distribution of the human body hair. Dermatologica, 1950;101(6):317-1.
  • 13. Shah PN. Human body hair: a quantitative study. Am J Obstet Gynecol 1957;73(6):1255-5.
  • 14. Francisco M. Camacho-M. Hirsutism, in Peytavi UB, Tosti A., Whiting DA, Trueb R (ed). Hair growth and disorders. Springer, New delhi, 2010;pp. 366
  • 15. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res, 2000; 54(5, 6):251-8.
  • 16. Camacho F. SAHA syndrome: Female androgenetic alopecia and hirsutism. Exp Dermatol 1999; 8(4):304-5.
  • 17. Esperanza LE, Fenske NA. Hyperandrogenism, insulin resistance, and acanthosis nigricans (HAIR-AN) syndrome: spontaneous remission in a 15-year-old girl. J Am Acad Dermatol 1996;34(5 pt 2):892–7.
  • 18. Kuroki R, Sadamoto Y, Imamura M, Abe Y, Higuchi K, Kato K, et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999;198(2):164-6.
  • 19. Magsino CH, Spencer J. Insulin receptor antibodies and insulin resistance. South Med J 1999;92(7):717-9.
  • 20. Harborne L, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005; 90(8):4593-8.
  • 21. Gullu S, Emral R, Asik M, Cesur M Tonyukuk V. Diagnostic value of Prostatic specific antigen in hirsute women. J Endocrinol Invest 2003;26(12):1198- 2.
  • 22. Rittmaster RS, Loriaux DL, Cutler GB Jr. Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women. J Clin Endocrinol Metab 1985;61(3):462-6.
  • 23. Emans SJ, Grace E, Woods ER, Mansfield J, Crigler JF Jr. Treatment with dexamethasone of androgen excess in adolescent patients. J Pediatr 1988;112(5):821-6.
  • 24. Shaw JC. Spironolactone in dermatological therapy. J Am Acad Dermatol 1991;24 (2 pt 1):236-43
  • 25. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52(5):587-94.
  • 26. Lowenstein EJ. Diagnosis and management of the dermatologic manifestation of polycystic ovary syndrome. Dermatol Ther 2006;19(4):210-3.
  • 27. Burkman RT Jr. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995;98 (1A):130-6.
  • 28. De Leo V, Fulghesu AM, la Marca A, Morgante G, Pasqui L, Talluri B, et al. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. Gynecol Endocrinol 2000;14 (6):411-6.
  • 29. Malhotra B, Noveck R, Behr D, Palmisano M. Percutaneous absorption and pharmacokinetics of eflornithine HCl 13% cream in women with unwanted facial hair. J Clin Pharmacol 2001;41(9): 972-8.
  • 30. Wagner RF Jr. Physical methods for the management of hirsutism. Cutis 1990; 45 (5):319-6.
  • 31. Dierickx CC. Hair removal by lasers and intense pulsed light sources. Semin Cutan Med Surg 2000; 19(4):267- 5.
  • 32. Sanchez LA, Perez M, Azziz R. Laser hair reduction in the hirsute patient: A critical assessment. Hum Reprod Update 2002;8 (2):169-1.
  • 33. Battle EF Jr, Hobbs LM. Laser-assisted hair removal for darker skin types. Dermatol Ther, 2004; 17 (2):177- 3.
  • 34. Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 2007; 57(1):54-9
  • 35. Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: A randomized trial. Dermatol Surg 2006; 32(10):1237-3.
  • 36. Pasquali R, Fabbri R, Venturoli S. et al. Effect of weight loss and antiandrogenic therapy on sex-hormone blood levels and insulin resistance in obese patients with polycystic ovary syndrome. Am J Obstet Gynecol, 1986;154(1): 139-4.
  • 37. Lanham MS, Lebovic DI, Domino SE. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 95 (3): 236-1.